In patients with heart failure, guideline-directed medical therapy is often mismanaged during acute decompensation, particularly with regard to beta-blocker therapy. In this entry, we discuss how to manage beta-blockers in patients with acute decompensated heart failure.
In this quick read, we provide an argument for why atenolol should be avoided in patients with compelling indications for beta blocker therapy.
Labetalol is a beta blocker with potent antihypertensive effects, and it may be administered orally or intravenously. The latter feature makes it especially useful for the acute management of elevated blood pressure but prolonged infusions can result in hemodynamic collapse. In this entry, two cases are discussed and recommendations are made for the appropriate management of continuous labetalol infusions.
Beta blockers remain a cornerstone in the management of several cardiovascular disorders yet many clinicians are reluctant to use them in the setting of cocaine abuse. In this entry, we take a look at the evidence.
Of the three beta blockers recommended in patients with heart failure with reduced ejection fraction, only carvedilol exerts antagonist effects at α1 receptors. However, its benefits in heart failure are presumably a result of myocardial β1 receptor inhibition, as the β1-selective agents bisoprolol and metoprolol succinate confer similar improvements in morbidity and mortality. So what’s the significance of α1 receptor blockade?
Intravenous diltiazem infusions (i.e., “dilt drips”) are commonly used for the management of atrial tachyarrhythmias but they tend to cause as many problems as they resolve.